Polpharma Celebrates Being First With Natalizumab In Europe

Proposed Biosimilar Rival To Tysabri Begins EMA Review; Sandoz Has Marketing Rights

Polpharma Biologics has claimed the first biosimilar natalizumab filing in Europe, after the European Medicines Agency accepted the firm’s marketing authorization application for review.

EU flag medal 1st first place
Polpharma has claimed the first biosimilar natalizumab filing • Source: Shutterstock

Polpharma Biologics says it has successfully filed the first natalizumab biosimilar in Europe, announcing that the European Medicines Agency has accepted the firm’s marketing authorization application for review.

Representing a rival to Biogen’s relapsing-remitting multiple sclerosis therapy Tysabri, the intravenous biosimilar offers “the same dosing regimen, presentation and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.